vs

Side-by-side financial comparison of FARMERS & MERCHANTS BANCORP INC (FMAO) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $32.5M, roughly 1.1× FARMERS & MERCHANTS BANCORP INC). FARMERS & MERCHANTS BANCORP INC runs the higher net margin — 30.2% vs -304.2%, a 334.4% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 21.0%). FARMERS & MERCHANTS BANCORP INC produced more free cash flow last quarter ($35.0M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 16.1%).

Rainier Bancorporation was the Seattle-based parent corporation of Rainier National Bank, a Washington state bank with branches throughout the state. Rainier traced its roots back to the National Bank of Commerce, which was founded by Richard Holyoke in 1889. The name Rainier National Bank was adopted in 1974. Rainier Bancorp expanded into Alaska with the purchase of Anchorage's People's Bank & Trust in 1983 and into Oregon with the purchase of Gresham's Mount Hood Security Bank in 1986, expa...

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

FMAO vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.1× larger
RXRX
$35.5M
$32.5M
FMAO
Growing faster (revenue YoY)
RXRX
RXRX
+660.8% gap
RXRX
681.7%
21.0%
FMAO
Higher net margin
FMAO
FMAO
334.4% more per $
FMAO
30.2%
-304.2%
RXRX
More free cash flow
FMAO
FMAO
$82.3M more FCF
FMAO
$35.0M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
16.1%
FMAO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FMAO
FMAO
RXRX
RXRX
Revenue
$32.5M
$35.5M
Net Profit
$9.8M
$-108.1M
Gross Margin
59.8%
Operating Margin
39.5%
-304.8%
Net Margin
30.2%
-304.2%
Revenue YoY
21.0%
681.7%
Net Profit YoY
16.8%
39.6%
EPS (diluted)
$0.72
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FMAO
FMAO
RXRX
RXRX
Q4 25
$32.5M
$35.5M
Q3 25
$31.3M
$5.2M
Q2 25
$29.6M
$19.2M
Q1 25
$28.1M
$14.7M
Q4 24
$26.8M
$4.5M
Q3 24
$25.5M
$26.1M
Q2 24
$25.1M
$14.4M
Q1 24
$24.1M
$13.8M
Net Profit
FMAO
FMAO
RXRX
RXRX
Q4 25
$9.8M
$-108.1M
Q3 25
$8.9M
$-162.3M
Q2 25
$7.7M
$-171.9M
Q1 25
$7.0M
$-202.5M
Q4 24
$8.4M
$-178.9M
Q3 24
$6.5M
$-95.8M
Q2 24
$5.7M
$-97.5M
Q1 24
$5.4M
$-91.4M
Gross Margin
FMAO
FMAO
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
FMAO
FMAO
RXRX
RXRX
Q4 25
39.5%
-304.8%
Q3 25
35.9%
-3327.6%
Q2 25
32.7%
-916.8%
Q1 25
31.2%
-1297.9%
Q4 24
39.2%
-4042.4%
Q3 24
31.7%
-377.1%
Q2 24
28.5%
-697.4%
Q1 24
28.2%
-698.4%
Net Margin
FMAO
FMAO
RXRX
RXRX
Q4 25
30.2%
-304.2%
Q3 25
28.3%
-3135.3%
Q2 25
26.0%
-894.2%
Q1 25
24.8%
-1373.3%
Q4 24
31.2%
-3935.5%
Q3 24
25.5%
-367.5%
Q2 24
22.6%
-676.6%
Q1 24
22.3%
-662.4%
EPS (diluted)
FMAO
FMAO
RXRX
RXRX
Q4 25
$0.72
$-0.17
Q3 25
$0.64
$-0.36
Q2 25
$0.56
$-0.41
Q1 25
$0.51
$-0.50
Q4 24
$0.61
$-0.56
Q3 24
$0.48
$-0.34
Q2 24
$0.42
$-0.40
Q1 24
$0.39
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FMAO
FMAO
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$370.9M
$1.1B
Total Assets
$3.4B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FMAO
FMAO
RXRX
RXRX
Q4 25
$743.3M
Q3 25
$659.8M
Q2 25
$525.1M
Q1 25
$500.5M
Q4 24
$594.4M
Q3 24
$427.6M
Q2 24
$474.3M
Q1 24
$296.3M
Total Debt
FMAO
FMAO
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
FMAO
FMAO
RXRX
RXRX
Q4 25
$370.9M
$1.1B
Q3 25
$361.8M
$1.0B
Q2 25
$350.8M
$919.1M
Q1 25
$344.6M
$933.9M
Q4 24
$335.2M
$1.0B
Q3 24
$335.4M
$524.6M
Q2 24
$322.7M
$584.4M
Q1 24
$317.7M
$401.2M
Total Assets
FMAO
FMAO
RXRX
RXRX
Q4 25
$3.4B
$1.5B
Q3 25
$3.4B
$1.4B
Q2 25
$3.3B
$1.3B
Q1 25
$3.4B
$1.3B
Q4 24
$3.4B
$1.4B
Q3 24
$3.4B
$726.5M
Q2 24
$3.3B
$775.9M
Q1 24
$3.3B
$557.8M
Debt / Equity
FMAO
FMAO
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FMAO
FMAO
RXRX
RXRX
Operating Cash FlowLast quarter
$36.7M
$-46.1M
Free Cash FlowOCF − Capex
$35.0M
$-47.3M
FCF MarginFCF / Revenue
107.8%
-133.1%
Capex IntensityCapex / Revenue
5.4%
3.5%
Cash ConversionOCF / Net Profit
3.75×
TTM Free Cash FlowTrailing 4 quarters
$56.7M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FMAO
FMAO
RXRX
RXRX
Q4 25
$36.7M
$-46.1M
Q3 25
$11.2M
$-117.4M
Q2 25
$1.1M
$-76.4M
Q1 25
$11.0M
$-132.0M
Q4 24
$32.5M
$-115.4M
Q3 24
$18.7M
$-59.2M
Q2 24
$9.7M
$-82.2M
Q1 24
$1.5M
$-102.3M
Free Cash Flow
FMAO
FMAO
RXRX
RXRX
Q4 25
$35.0M
$-47.3M
Q3 25
$10.7M
$-117.6M
Q2 25
$385.0K
$-79.6M
Q1 25
$10.6M
$-133.8M
Q4 24
$30.6M
$-116.7M
Q3 24
$18.3M
$-63.8M
Q2 24
$9.2M
$-83.4M
Q1 24
$1.3M
$-109.0M
FCF Margin
FMAO
FMAO
RXRX
RXRX
Q4 25
107.8%
-133.1%
Q3 25
34.3%
-2272.5%
Q2 25
1.3%
-413.9%
Q1 25
37.8%
-907.4%
Q4 24
114.1%
-2567.7%
Q3 24
71.7%
-244.6%
Q2 24
36.5%
-578.5%
Q1 24
5.3%
-789.9%
Capex Intensity
FMAO
FMAO
RXRX
RXRX
Q4 25
5.4%
3.5%
Q3 25
1.5%
4.7%
Q2 25
2.4%
16.4%
Q1 25
1.4%
12.4%
Q4 24
7.0%
28.6%
Q3 24
1.4%
17.5%
Q2 24
2.3%
8.2%
Q1 24
0.9%
48.2%
Cash Conversion
FMAO
FMAO
RXRX
RXRX
Q4 25
3.75×
Q3 25
1.26×
Q2 25
0.14×
Q1 25
1.58×
Q4 24
3.87×
Q3 24
2.86×
Q2 24
1.71×
Q1 24
0.28×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons